HUT68355A - Method for production of vaccine serving for treatment of hiv infection - Google Patents

Method for production of vaccine serving for treatment of hiv infection Download PDF

Info

Publication number
HUT68355A
HUT68355A HU9300686A HU9300686A HUT68355A HU T68355 A HUT68355 A HU T68355A HU 9300686 A HU9300686 A HU 9300686A HU 9300686 A HU9300686 A HU 9300686A HU T68355 A HUT68355 A HU T68355A
Authority
HU
Hungary
Prior art keywords
recombinant
hiv
protein
vaccine
envelope
Prior art date
Application number
HU9300686A
Other languages
English (en)
Hungarian (hu)
Other versions
HU9300686D0 (en
Inventor
Gale E Smith
Franklin Volvovitz
Original Assignee
Microgenesys Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Microgenesys Inc filed Critical Microgenesys Inc
Publication of HU9300686D0 publication Critical patent/HU9300686D0/hu
Publication of HUT68355A publication Critical patent/HUT68355A/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/14011—Baculoviridae
    • C12N2710/14041—Use of virus, viral particle or viral elements as a vector
    • C12N2710/14043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vectore
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
HU9300686A 1991-06-11 1992-06-10 Method for production of vaccine serving for treatment of hiv infection HUT68355A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US71415291A 1991-06-11 1991-06-11

Publications (2)

Publication Number Publication Date
HU9300686D0 HU9300686D0 (en) 1993-06-28
HUT68355A true HUT68355A (en) 1995-06-28

Family

ID=24868938

Family Applications (1)

Application Number Title Priority Date Filing Date
HU9300686A HUT68355A (en) 1991-06-11 1992-06-10 Method for production of vaccine serving for treatment of hiv infection

Country Status (18)

Country Link
EP (1) EP0542998A1 (et)
JP (1) JPH06501851A (et)
CN (1) CN1068266A (et)
AU (2) AU2193192A (et)
BG (1) BG97519A (et)
CA (1) CA2087732A1 (et)
EE (1) EE9400183A (et)
FI (1) FI930577L (et)
HU (1) HUT68355A (et)
IE (1) IE921875A1 (et)
IL (1) IL102092A (et)
LT (1) LT3365B (et)
MX (1) MX9202781A (et)
PL (1) PL297849A1 (et)
PT (1) PT100584A (et)
SK (1) SK18993A3 (et)
WO (1) WO1992022654A1 (et)
ZA (1) ZA924150B (et)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE40786E1 (en) * 1984-03-16 2009-06-23 The United States Of America As Represented By The Secretary Of The Army Vaccines against intracellular pathogens using antigens encapsulated within biodegradable-biocompatible microspheres
US6017536A (en) * 1993-06-07 2000-01-25 Trimeris, Inc. Simian immunodeficiency virus peptides with antifusogenic and antiviral activities
US5464933A (en) * 1993-06-07 1995-11-07 Duke University Synthetic peptide inhibitors of HIV transmission
US6479055B1 (en) 1993-06-07 2002-11-12 Trimeris, Inc. Methods for inhibition of membrane fusion-associated events, including respiratory syncytial virus transmission
WO1995017515A1 (en) * 1993-12-23 1995-06-29 University Technologies International Inc. Methods of expressing proteins in insect cells and methods of killing insects
AU723537B2 (en) 1995-06-07 2000-08-31 Trimeris Inc. The treatment of HIV and other viral infections using combinatorial therapy
US6395541B1 (en) 1996-05-23 2002-05-28 The Rockefeller University Methods for the identification of compounds capable of inhibiting HIV-1 viral replication employing murine cell lines expressing human topoisomerase I
US6319504B1 (en) 1996-06-24 2001-11-20 University Of Maryland Biotechnology Institute Treatment and prevention of HIV infection by administration of derivatives of human chorionic gonadotropin
US6077662A (en) * 1996-11-27 2000-06-20 Emory University Virus-like particles, methods and immunogenic compositions
US6214540B1 (en) 1997-03-26 2001-04-10 University Of Maryland Biotechnology Institute Chemokines that inhibit immunodeficiency virus infection and methods based thereon
US6583109B1 (en) 1997-06-24 2003-06-24 Robert C. Gallo Therapeutic polypeptides from β-hCG and derivatives
US6548631B1 (en) 1997-09-16 2003-04-15 BIOMéRIEUX, INC. Macrophage derived chemokine (MDC) as an anti-viral agent for the treatment and prevention of lentivirus infection
US6750008B1 (en) 1999-07-09 2004-06-15 Trimeris, Inc. Methods and compositions for inhibition of membrane fusion-associated events, including HIV transmission
US7994278B1 (en) 1999-08-06 2011-08-09 Nobel Biosciences Llc Biologically active polypeptides derived from a novel early stage pregnancy factor designated maternin (MA)
US6623741B1 (en) 2000-02-29 2003-09-23 Trimeris, Inc. Methods and compositions for inhibition of membrane fusion-associated events including RSV transmission
AUPS065002A0 (en) 2002-02-20 2002-03-14 Immunaid Pty Ltd Strategy for retroviral immunotherapy
JP2006509039A (ja) * 2002-12-03 2006-03-16 ユニバーシティ オブ マサチューセッツ 多価初代ｈｉｖ−１糖タンパク質ｄｎａワクチンおよびワクチン接種方法
PL1692516T3 (pl) 2003-10-24 2011-05-31 Immunaid Pty Ltd Sposób terapii
GT200800303A (es) 2007-12-24 2009-09-18 Combinacion anti-retroviral
PT2435825E (pt) 2009-05-27 2015-11-02 Biotempus Ltd Métodos para o tratamento de doenças
AU2012298125B2 (en) 2011-08-19 2015-09-24 Immortal Spirit Limited Antibody and antibody-containing composition
CN102961760B (zh) * 2011-09-01 2017-07-18 常州文松生物技术有限公司 重叠肽作为制备皮肤试验和检测特异性细胞免疫的试剂及其应用

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL89118A0 (en) * 1988-02-03 1989-08-15 Microgenesys Inc Vaccine containing polypeptides derived from the envelope gene of human immunodeficiency virus type 1

Also Published As

Publication number Publication date
SK18993A3 (en) 1993-10-06
FI930577A7 (fi) 1993-03-24
MX9202781A (es) 1993-04-01
HU9300686D0 (en) 1993-06-28
IL102092A0 (en) 1993-01-14
AU4028895A (en) 1996-02-22
EE9400183A (et) 1995-12-15
LTIP335A (en) 1995-01-31
AU2193192A (en) 1993-01-12
LT3365B (en) 1995-07-25
PL297849A1 (en) 1994-01-24
BG97519A (bg) 1994-03-24
JPH06501851A (ja) 1994-03-03
IL102092A (en) 1996-11-14
ZA924150B (en) 1993-02-24
PT100584A (pt) 1993-07-30
FI930577A0 (fi) 1993-02-10
IE921875A1 (en) 1992-12-16
CA2087732A1 (en) 1992-12-12
FI930577L (fi) 1993-03-24
WO1992022654A1 (en) 1992-12-23
EP0542998A1 (en) 1993-05-26
CN1068266A (zh) 1993-01-27

Similar Documents

Publication Publication Date Title
HUT68355A (en) Method for production of vaccine serving for treatment of hiv infection
AU732809B2 (en) Compositions and methods for treating viral infections
US5166050A (en) Monoclonal antibodies and peptides useful in treating and diagnosing HIV infections
EP0546787A2 (en) Expression of specific immunogens using viral antigens
JPH10503933A (ja) 抗原的に標識した非感染性レトロウィルス様粒子
CH675728A5 (et)
EP0689586B1 (en) Vpr function and activity
KR100194079B1 (ko) Hiv 감염 예방 또는 치료용 제약학적 조성물 및 이의 제조방법
EP0327180A2 (en) Vaccine containing polypeptides derived from the envelope gene of human immunodeficiency virus type 1
US9486518B2 (en) Membrane proximal region of HIV GP41 anchored to the lipid layer of a virus-like particle vaccine
HU211505A9 (hu) HIV-fertőzés kezelésére szolgáló vakcinakészítmény Az átmeneti oltalom az 1-15. igénypontokra vonatkozik.
US20080267989A1 (en) Hiv Gp-41-Membrane Proximal Region Arrayed On Hepatitis B Surface Antigen Particles as Novel Antigens
US6290963B1 (en) Anti-HIV compositions containing native and recombinant peptides
US5486473A (en) A DNA coding for a Flavivirus antigen
WO1989005820A1 (en) Hiv-related antigens and antibodies
SI9200420A (sl) Vakcina proti infekciji, ki jo povzroča človeški virus imunodeficience
HRP921484A2 (en) Vaccine and treatment method of human immunodeficiency virus infection
LV10492B (en) Vaccine and treatment method for human immunodeficiency virus
AU2006200454A1 (en) Compositions and methods for treating viral infections
LV10497B (en) A method for obtaining a vaccine comprising polypeptides derived from the HIV-1 virus envelope gene
AU2004201321A1 (en) Compositions and methods for treating viral infections
AU2004208648A1 (en) Compositions and methods for treating infections
FR2593519A1 (fr) Vaccin contre le syndrome immunodeficitaire acquis et intermediaires pour la preparation de ce vaccin
DD283936A5 (de) Verfahren zur herstellung von peptiden, die in der lage sind immunologisch die neutralisierenden bereiche von hiv proteinen nachzuahmen

Legal Events

Date Code Title Description
DFA9 Temporary protection cancelled due to abandonment